Low-dose aspirin for cardiovascular protection in diabetes: Is it still justified?

Deborah Wake*, John McKnight

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Aspirin use in people with established cardiovascular disease (CVD) is well founded; however, its use in primary prevention, even in high-risk populations, has never been proven beneficial. Despite the lack of evidence, many guidelines advocate the use of low-dose aspirin in older people with diabetes. This article reviews the literature on this topic, including the POPADAD (Prevention of Progression of Arterial Disease and Diabetes) study, published recently in the British Medical Journal. This prospective randomised trial addresses this issue in a UK-based population with diabetes and asymptomatic peripheral vascular disease. It provides further evidence that aspirin does not afford cardiovascular protection in the absence of proven symptomatic CVD.

Original languageEnglish
Pages (from-to)15-19
Number of pages5
JournalDiabetes and Primary Care
Volume11
Issue number1
Publication statusPublished - 7 Apr 2009

Keywords

  • Aspirin
  • Cardiovascular disease
  • Diabetes
  • Primary prevention

Fingerprint Dive into the research topics of 'Low-dose aspirin for cardiovascular protection in diabetes: Is it still justified?'. Together they form a unique fingerprint.

Cite this